Oventus is a Brisbane-based medical device company established in 2012. In 2013, Oventus worked with the CSIRO to develop a new style of bespoke mouthguard that has the potential to change the lives of millions of snorers and people with sleep-disordered breathing around the world.
The result is the O2Vent (formerly the Oventus Clearway Device) – an oral device with a unique separate airway incorporated into its patented design.
Oventus aims to become a world leader in sleep-disordered breathing treatment by commercialising a suite of revolutionary oral devices like this that provide increased airflow to people who snore and suffer from sleep-disordered breathing.
The company is managed by founder and Clinical Director Dr Chris Hart BSc. BDSc.(Hons) M.Phil.(Cantab) and Chief Executive Officer Neil Anderson.
About the Oventus team
DR CHRIS HART
As Clinical Director of Oventus, Dr Chris Hart is overseeing the launch of the O2Vent to patients and through clinicians.
Chris also sees patients to fit the O2Vent in the Oventus office in Brisbane.
Chris graduated from the University of Queensland in 1998 with a Bachelor of Dental Science with Honours and a Bachelor of Science in Biochemistry. He has studied at Cambridge University where he graduated with a Master of Philosophy in Biomedical Science in 1999.
Prior to establishing Oventus, Chris owned and managed a multi-site national dental practice, training institute and management consultancy which he recently sold to private equity investors. He now works full time as the Oventus Clinical Director.
Chris also acts as an adviser to various bodies within the dental industry as well as the health care sector more broadly on the commercial aspects of health care delivery.
MANAGING DIRECTOR AND CEO
An experienced company executive and biomaterial scientist, Neil started working with Dr Chris Hart in 2013, to develop and commercialise the O2Vent™ and bring it to market. Neil has been responsible for managing the collaboration process with the CSIRO to develop a remotely-managed computer aided detection (CAD) imaging and 3D printing manufacturing platform, as well as the patent portfolio, quality systems and regulatory clearances for the product to date.
Neil has 30 years’ experience in commercialising medical devices and managing the process from conception to market release including applied research, developing prototypes and testing, product development, manufacturing, regulatory submissions and clinical trials.
Prior to taking on the role with Oventus, Neil founded and held the role of Chief Executive Officer of CathRx for 10 years.
In this role, Neil managed the process from the invention of the company’s technology through to commercialising a range of products leading to sales in Europe.
Neil has a Bachelor of Applied Science (Hons) and a Diploma of Management and is a Graduate of the Institute of Company Directors (GAICD).